Passion for People Development
pipeline
Three programs targeting hospital acquired infections.
SLM500
Antibacterial · peptide-polyketide
WHO priority pathogens
Broad spectrum activity against Gram-negative and Gram-positive resistant clinical isolates. New dual binding site at the gyrase dimer interface.
For the therapy of urinary tract infections (UTI), lung infections, and other systemic bacterial infections.
_____________________________________________
TRL 5 · IND-ENABLING
SLM100
Antifungal · macrocycle
Systemic fungal infections
Dual inhibitor of two essential fungal membrane enzymes. Active against WHO critical priority pathogens Candida and Aspergillus species.
Supporting patients affected by systemic fungal infections.
_____________________________________________
TRL 4 · LEAD OPTIMIZATION
SLM300
Antibacterial · small molecule
Gram-negative infections
Dual inhibitor of bacterial membrane transporters. In-vivo efficacy confirmed against resistant E. coli.
Life saving therapy for patients suffering from uncomplicated urinary tract infection (uUTI).
_____________________________________________
TRL 3 · LEAD OPTIMIZATION
Com
Copyright© 2026 Selmod GmbH
All Rights Reserved.
